Tuva Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
NY open-source healthcare claims data transformation platform serving 1,500+ practitioners at Oscar Health and MultiCare; YC W22 $6M Virtue-backed first health system-backed open-source data platform competing with Datavant for healthcare analytics engineering.
About
Tuva Health is a New York-based open-source healthcare data transformation company — backed by Y Combinator (W22) with $6 million raised including a $5 million seed round in December 2024 led by Virtue with Box Group, YC, and health technology angels, plus MultiCare Capital Partners (investment from MultiCare Health System making Tuva the first open-source data platform backed by a health system) in February 2025 — operating the Tuva Project, the world's first open-source healthcare data transformation platform that enables payers, providers, and pharmaceutical companies to convert raw claims and EHR datasets into analytics-ready data models through built-in normalization, quality testing, and clinical enrichment. Tuva serves 1,500+ healthcare data practitioners and 30+ partners including Oscar Health and MultiCare.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.